C R Bard Inc  

(Public, NYSE:BCR)   Watch this stock  
Find more results for BCR
250.48
-0.30 (-0.12%)
After Hours: 250.48 0.00 (0.00%)
Mar 28, 4:52PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 248.80 - 250.95
52 week 197.35 - 252.25
Open 250.40
Vol / Avg. 687,729.00/440,741.00
Mkt cap 18.11B
P/E 35.63
Div/yield 0.26/0.42
EPS 7.03
Shares 72.31M
Beta 0.64
Inst. own 91%
Jan 26, 2017
Q4 2016 C R Bard Inc Earnings Release (Estimated)
Jan 10, 2017
C R Bard Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 16.50% 14.31%
Operating margin 22.39% 19.02%
EBITD margin - 31.20%
Return on average assets 12.06% 10.47%
Return on average equity 37.50% 33.78%
Employees 16,300 -
CDP Score - -

Address

730 Central Ave
NEW PROVIDENCE, NJ 07974-1139
United States - Map
+1-908-2778000 (Phone)
+1-908-2778412 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

Officers and directors

Timothy M. Ring Chairman of the Board, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John H. Weiland President, Vice Chairman of the Board, Chief Operating Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James C. Beasley Group President
Age: 53
Bio & Compensation  - Reuters
Timothy P. Collins Group President
Age: 56
Bio & Compensation  - Reuters
John P. Groetelaars Group President
Age: 50
Bio & Compensation  - Reuters
Christopher S. Holland Chief Financial Officer, Senior Vice President
Age: 50
Bio & Compensation  - Reuters
Samrat S. Khichi Senior Vice President, General Counsel, Secretary
Age: 49
Bio & Compensation  - Reuters
John A. DeFord Ph.D. Senior Vice President - Science, Technology and Clinical Affairs
Age: 55
Bio & Compensation  - Reuters
Frank Lupisella Jr. Vice President, Controller
Age: 56
Bio & Compensation  - Reuters
Betty D. Larson Vice President - Human Resources
Age: 41
Bio & Compensation  - Reuters